240 related articles for article (PubMed ID: 16876402)
1. Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.
Tully DC; Liu H; Chatterjee AK; Alper PB; Epple R; Williams JA; Roberts MJ; Woodmansee DH; Masick BT; Tumanut C; Li J; Spraggon G; Hornsby M; Chang J; Tuntland T; Hollenbeck T; Gordon P; Harris JL; Karanewsky DS
Bioorg Med Chem Lett; 2006 Oct; 16(19):5112-7. PubMed ID: 16876402
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S.
Chatterjee AK; Liu H; Tully DC; Guo J; Epple R; Russo R; Williams J; Roberts M; Tuntland T; Chang J; Gordon P; Hollenbeck T; Tumanut C; Li J; Harris JL
Bioorg Med Chem Lett; 2007 May; 17(10):2899-903. PubMed ID: 17382545
[TBL] [Abstract][Full Text] [Related]
3. Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors.
Tully DC; Liu H; Chatterjee AK; Alper PB; Williams JA; Roberts MJ; Mutnick D; Woodmansee DH; Hollenbeck T; Gordon P; Chang J; Tuntland T; Tumanut C; Li J; Harris JL; Karanewsky DS
Bioorg Med Chem Lett; 2006 Oct; 16(19):5107-11. PubMed ID: 16876407
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
Tully DC; Liu H; Alper PB; Chatterjee AK; Epple R; Roberts MJ; Williams JA; Nguyen KT; Woodmansee DH; Tumanut C; Li J; Spraggon G; Chang J; Tuntland T; Harris JL; Karanewsky DS
Bioorg Med Chem Lett; 2006 Apr; 16(7):1975-80. PubMed ID: 16446091
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
[TBL] [Abstract][Full Text] [Related]
6. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
7. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
[TBL] [Abstract][Full Text] [Related]
8. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
Barrett DG; Boncek VM; Catalano JG; Deaton DN; Hassell AM; Jurgensen CH; Long ST; McFadyen RB; Miller AB; Miller LR; Payne JA; Ray JA; Samano V; Shewchuk LM; Tavares FX; Wells-Knecht KJ; Willard DH; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2005 Aug; 15(15):3540-6. PubMed ID: 15982880
[TBL] [Abstract][Full Text] [Related]
9. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
[TBL] [Abstract][Full Text] [Related]
10. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
[TBL] [Abstract][Full Text] [Related]
11. Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2004 Oct; 14(19):4897-902. PubMed ID: 15341947
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.
Boros EE; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Paulick MG; Shewchuk LM; Thompson JB; Willard DH; Wright LL
Bioorg Med Chem Lett; 2004 Jul; 14(13):3425-9. PubMed ID: 15177446
[TBL] [Abstract][Full Text] [Related]
13. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.
Barrett DG; Catalano JG; Deaton DN; Long ST; Miller LR; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2004 May; 14(10):2543-6. PubMed ID: 15109647
[TBL] [Abstract][Full Text] [Related]
14. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.
Black WC; Bayly CI; Davis DE; Desmarais S; Falgueyret JP; Léger S; Li CS; Massé F; McKay DJ; Palmer JT; Percival MD; Robichaud J; Tsou N; Zamboni R
Bioorg Med Chem Lett; 2005 Nov; 15(21):4741-4. PubMed ID: 16154747
[TBL] [Abstract][Full Text] [Related]
15. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
Crane SN; Black WC; Palmer JT; Davis DE; Setti E; Robichaud J; Paquet J; Oballa RM; Bayly CI; McKay DJ; Somoza JR; Chauret N; Seto C; Scheigetz J; Wesolowski G; Massé F; Desmarais S; Ouellet M
J Med Chem; 2006 Feb; 49(3):1066-79. PubMed ID: 16451072
[TBL] [Abstract][Full Text] [Related]
16. A structural screening approach to ketoamide-based inhibitors of cathepsin K.
Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Wells-Knecht KJ; Wright LL
Bioorg Med Chem Lett; 2005 May; 15(9):2209-13. PubMed ID: 15837295
[TBL] [Abstract][Full Text] [Related]
17. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
Nair LG; Sannigrahi M; Bogen S; Pinto P; Chen KX; Prongay A; Tong X; Cheng KC; Girijavallabhan V; George Njoroge F
Bioorg Med Chem Lett; 2010 Jan; 20(2):567-70. PubMed ID: 20004570
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors.
Kowalchick JE; Leiting B; Pryor KD; Marsilio F; Wu JK; He H; Lyons KA; Eiermann GJ; Petrov A; Scapin G; Patel RA; Thornberry NA; Weber AE; Kim D
Bioorg Med Chem Lett; 2007 Nov; 17(21):5934-9. PubMed ID: 17827003
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.
Greco MN; Hawkins MJ; Powell ET; Almond HR; de Garavilla L; Hall J; Minor LK; Wang Y; Corcoran TW; Di Cera E; Cantwell AM; Savvides SN; Damiano BP; Maryanoff BE
J Med Chem; 2007 Apr; 50(8):1727-30. PubMed ID: 17361995
[TBL] [Abstract][Full Text] [Related]
20. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
